Amphastar Pharmaceuticals Inc vs Goodyear Tire & Rubber Co — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Goodyear Tire & Rubber Co trades at $6.1 (market cap $1.74B). The key difference: Goodyear Tire & Rubber Co is far larger — about 2× Amphastar Pharmaceuticals Inc's market cap, and Amphastar Pharmaceuticals Inc is trading nearer its 52-week high, Goodyear Tire & Rubber Co nearer its low. Which is the better fit depends on your goals.
| AMPH | GT | |
|---|---|---|
Market Cap | $863.95M | $1.74B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $10.54 |
52-Week Low | $16.87 | $5.58 |
Enterprise Value | $1.26B | $9.09B |
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Goodyear Tire & Rubber (GT) is trading at $6.44, down 4.73% today, reflecting ongoing pressure from declining tire volumes and a challenging cost environment. The stock exhibits a bearish technical trend with oversold RSI levels, while fundamentals show a net loss of $1.72 billion in 2025 despite positive cash flow. Recent Q2 2026 results missed earnings expectations but beat revenue estimates, highlighting mixed operational performance amid market headwinds.
The outlook remains cautious with persistent profitability challenges and high debt levels offsetting low valuation multiples. Investment opportunity hinges on volume recovery and cost management improvements, but risks include sustained margin pressure and competitive threats. Analyst sentiment is mixed with a slight hold bias, underscoring the need for operational turnaround to drive shareholder value.
Trailing returns across standard periods
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →